BRANMOOR
THURSDAY · 14 MAY 2026

FDA Recall D-1429-2012

Eagle Pharmaceuticals Inc. · Woodcliff Lake, NJ

Class I — life-threatening Terminated 549 days on record

Highest impact — Class I recall — FDA determination of strong likelihood of serious adverse health consequence or death.

Product

Argatroban Injection 50 mg per 50ml (1 mg per ml) For Intravenous Infusion Only, a) Single Use Vial (NDC 42367-203-07), b) 10 Single Use Vials(NDC 42367-203-84), Rx Only, Manufactured by: Cipla LTD, India, Manufactured for: Eagle Pharmaceuticals, Inc. Woodcliff Lake, NJ 07677 USA, Marketed by: The Medicines Company, Parsippany, NJ 07054 USA

Lot / code: Lot #V10189, Lot #V10191, Lot #V10194, Exp 01/13; Lot #V10223; Exp 02/13

Quantity: 19,660 vials

Reason for recall

A complaint was received from a hospital pharmacy on 11/10/11 for crystalline particulates in a single vial from Lot V10194. Additional small visible particles consisting of fibers were identified.

Recall record

Recall number
D-1429-2012
Classification
Class I
Status
Terminated
Voluntary or mandated
Voluntary: Firm initiated
Firm notification
Letter
Distribution
New Jersey
Recall initiated
2011-12-02
Classified by FDA Center
2012-07-31
FDA published
2012-08-08
Terminated
2013-06-03
Recalling firm
Eagle Pharmaceuticals Inc.
Firm location
Woodcliff Lake, NJ

‹ All recalls